본문 바로가기

US · 21 CFR

21 CFR Part 1271

Human Cells, Tissues, and Cellular and Tissue-Based Products

eCFR, up to date as of 2026-11-12

조항 목차

  1. 1271.1What are the purpose and scope of this part?
  2. 1271.3How does FDA define important terms in this part?
  3. 1271.10Are my HCT/P's regulated solely under section 361 of the PHS Act and the regulations in this part, and if so what must I do?
  4. 1271.15Are there any exceptions from the requirements of this part?
  5. 1271.20If my HCT/P's do not meet the criteria in § 1271.10, and I do not qualify for any of the exceptions in § 1271.15, what regulations apply?
  6. 1271.21When do I register, submit an HCT/P list, and submit updates?
  7. 1271.22How do I register and submit an HCT/P list?
  8. 1271.23How is a waiver from the electronic format requirements requested?
  9. 1271.25What information is required for establishment registration and HCT/P listing?
  10. 1271.26When must I amend my establishment registration?
  11. 1271.27Will FDA assign me a registration number?
  12. 1271.37Will establishment registrations and HCT/P listings be available for inspection, and how do I request information on registrations and listings?
  13. 1271.45What requirements does this subpart contain?
  14. 1271.47What procedures must I establish and maintain?
  15. 1271.50How do I determine whether a donor is eligible?
  16. 1271.55What records must accompany an HCT/P after the donor-eligibility determination is complete; and what records must I retain?
  17. 1271.60What quarantine and other requirements apply before the donor-eligibility determination is complete?
  18. 1271.65How do I store an HCT/P from a donor determined to be ineligible, and what uses of the HCT/P are not prohibited?
  19. 1271.75How do I screen a donor?
  20. 1271.80What are the general requirements for donor testing?
  21. 1271.85What donor testing is required for different types of cells and tissues?
  22. 1271.90Are there other exceptions and what labeling requirements apply?
  23. 1271.145Prevention of the introduction, transmission, or spread of communicable diseases.
  24. 1271.150Current good tissue practice requirements.
  25. 1271.155Exemptions and alternatives.
  26. 1271.160Establishment and maintenance of a quality program.
  27. 1271.170Personnel.
  28. 1271.180Procedures.
  29. 1271.190Facilities.
  30. 1271.195Environmental control and monitoring.
  31. 1271.200Equipment.
  32. 1271.210Supplies and reagents.
  33. 1271.215Recovery.
  34. 1271.220Processing and process controls.
  35. 1271.225Process changes.
  36. 1271.230Process validation.
  37. 1271.250Labeling controls.
  38. 1271.260Storage.
  39. 1271.265Receipt, predistribution shipment, and distribution of an HCT/P.
  40. 1271.270Records.
  41. 1271.290Tracking.
  42. 1271.320Complaint file.
  43. 1271.330Applicability.
  44. 1271.350Reporting.
  45. 1271.370Labeling.
  46. 1271.390Applicability.
  47. 1271.400Inspections.
  48. 1271.420HCT/Ps offered for import.
  49. 1271.440Orders of retention, recall, destruction, and cessation of manufacturing.
표지·목차 원문

Authority:42 U.S.C. 216, 243, 263a, 264, 271.

Source:66 FR 5466, Jan. 19, 2001, unless otherwise noted.

출처: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · 수집일 2026-11-16

Weekly Newsletter

FDA·EU·식약처 실사 지적, 매주 받아 보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

확인 메일의 버튼을 누르면 구독이 완료됩니다 · 언제든 해지할 수 있습니다